Saturday, October 3, 2026

USD/CNH Is 2% Down In The Last 21 Sessions

ViaNews Editorial Team

December 21, 2023

USD/CNH Is 2% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.34% for the last 21 sessions. At 06:11 EST on Thursday, 21 December, USD/CNH (USDCNH) is $7.14.

USD/CNH's yearly highs and lows, it's 0.034% up from its 52-week low and 0.084% down from its 52-week high.

News about

  • Usd/jpy swamped near 144.00 after failing to vault over 145.00 on Tuesday. According to FXStreet on Tuesday, 19 December, "Intraday action finds the USD/JPY pinned into the 200-day Simple Moving Average (SMA) near the 144.00 handle, after hitting a Tuesday high that fell just shy of the 145.00 major price level.", "Daily candlesticks show the USD/JPY churning at the 200-day SMA as medium-term momentum drains out of the pair, leaving bids to waffle into long-term median prices."
  • Usd/jpy: boj puts the fate of the yen in the hands of the fed or the dollar – commerzbank. According to FXStreet on Tuesday, 19 December, "In other words, in the end, it will never be about Yen strength, but always about Dollar weakness when USD/JPY falls (for example, because Fed rate cut expectations are rising, as is the case now). "
  • Usd/jpy corrects from 145.00 as fed’s rate cut expectations soar. According to FXStreet on Wednesday, 20 December, "The USD/JPY pair corrects to near 143.50 amid expectations that the Federal Reserve (Fed) will start lowering borrowing interest rates earlier than projected by policymakers. "
  • Usd/jpy rallies nearing 145.00 fuelled by a dovish boj. According to FXStreet on Tuesday, 19 December, "This has boosted the USD/JPY about 1.25% higher on the day so far, to reach intra-day highs near 145.00."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com